Yuma Therapeutics Corp., of New York, received a $249,810 grant from the Alzheimer's Drug Discovery Foundation to develop small molecules against Alzheimer's. The award will fund work to develop Yuma's disease-modifying compounds designed to target neurofibrillary tangles resulting from abnormal forms of tau protein.